

Supplementary Table 2

Table S2 Summary of the previous reports on histone H3 K27-mutant diffuse midline glioma cohort studies

Author / Country Journal. Year [Ref]	Number of patients	Median age, (range)	Age group	Sex (M, F)	Median OS (months)		Prognostic factors
Feng J. et al. / China Human Pathol. 2015 [16]	25	N/A	N/A	N/A	N/A		good: none poor: brainstem
Meyronet D. et al. / France Neuro Oncol. 2017 [33]	21	32, (18–82)	21adults	9, 12	19.6 (n=21)		N/A*
Yoshimoto K. et al. / Japan Brain Tumor Pathol. 2017 [60]	10	15, (5–66)	10(adults and pediatrics)	6, 4	15.7 (n=10)		N/A*
Aboian M.S. et al. / USA AJNR Am J Neuroradiol. 2017 [1]	24	9(mean), (2–19)	24 pediatrics	17, 7	N/A		N/A*
Wang L. et al. / China Human Pathol. 2018 [55]	61	27, (N/A)	26 pediatrics 35 adults	13, 13 19, 16	13.1 (n=61)		N/A*
Bozkurt SU. et al. / Turkey Childs Nerv Syst. 2018 [7]	31	9.2±3.8, (mean±SD)	31pediatrics	13, 18	N/A		N/A*
Kleinschmidt et al. / USA Clin Neuropathol. 2018 [26]	28	15, (3–81)	15 pediatrics 13 adults	7, 7 4, 9	6.9 (n=15) 8.4 (n=13)		N/A*
Karremann M. et al. / Germany Neuro Oncol. 2018 [25]	62	N/A, (0–18)	56 H3.3, 6 H3.1	30, 31	12.5 (n=61)		N/A*
Ebrahimi A et al. / Germany J Cancer Res Clin Oncol. 2019 [14]	41	29, (4–73)	12 pediatrics 29 adults	5, 7 19, 10	2.7 (n=7) 4.0 (n=19)		N/A*
Karlwee V. et al. / Japan Pathobiology. 2019 [24]	12	30, (6–56)	4 pediatrics 8 adults	2, 2 6, 2	14.6 (n=12)		good: none poor: <i>EZH2</i> expression
Shreck KC. et al. / USA J Neurooncol. 2019 [42]	18	38, (30–68)	18 adults	8, 10	17.6 (n=18)		N/A*
Schulte JD. et al. / USA Neuro Oncol adv. 2020 [44]	60	32, (18–71)	60 adults	33, 27	27.6 (n=60)		good: adults, RT poor: none
Enomoto T et al. / Japan Neurol Med Chir. 2020 [15]	11	N/A	N/A	N/A	17.0 (n=11)		N/A*
Wang Y. et al. / China Front Oncol. 2021 [56]	43	38, (3–75)	13 pediatrics 30 adults	6, 7 20, 10	12.8 (n=43)		good: preOP KPS ≥ 70, RT poor: <i>p53</i> overexpression
Thust S. et al. / UK Quant Imaging Med Surg. 2021 [51]	15	19, (14–64)	15(adults and pediatrics)	6, 9	N/A		not mentioned
Park C. et al. / Korea Cancer Res Treat. 2021 [35]	33	39, (20–70)	33 adults	17, 16	21.8 (n=33)		not identified
Schuller U. et al. / Germany Acta Neuropathol. 2021 [43]	83	17(n=78), (3–58)	83(adults and pediatrics)	45, 36 (n=81)	9.0 (n=63)		good: adults, supratentorial locations, <i>FGFR1</i> mutation poor: <i>TP53</i> mutation
Zhao et al. / China BMC Neurol. 2022 [61]	14	19, (8–70)	14(adults and pediatrics)	11, 3	16.8 (mean)		N/A*
Zheng L. et al. / China Am J Surg Pathol. 2022 [62]	164	23, (3–71)	70 pediatrics 94 adults	36, 34 52, 42	5.0 (n=N/A) 16.0 (n=N/A)	mOS 10.5 (n=122)	good: tumor diameter ≤ 3cm, Ki-67 ≤ 5% poor: pediatrics, brainstem, <i>ATRX</i> expression
Jang SW. et al. / Korea Brain Tumor Res Treat. 2022 [23]	24	24(mean), (4–73)	11 pediatrics 13 adults	6, 5 6, 7	10.4 (n=24)		not identified
Present study	93	31, (4–78)	26 pediatrics 67 adults	18, 8 37, 30	15.3 (n=24) 16.7 (n=63)	mOS 16.6 (n=87)	good: female sex, pre OP KPS ≥ 80, RT ≥ 50Gy poor: none

N/A: Not Available, * compared with H3 wild type